ASH 2025 | Choosing between imatinib and nilotinib in CML
Weiming Li
• 7 Dec 2025
In this video, Weiming Li, MD, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, discusses the findings of a real-world multicenter study that found comparable treatment-free remission (TFR) outcomes in patients with chronic myeloid leukemia (CML) treated with imatinib versus nilotinib. Dr Li notes that this information can aid clinicians in selecting between these two tyrosine kinase inhibitors (TKIs) when managing patients with the disease. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
